



AMERISE BIOSCIENCES LIMITED

CIN: L29199GJ1984PLC007195

(Formerly Known as AMRADEEP INDUSTRIES LIMITED)

Date: 03.02.2025

To,
Listing Department,
BSE Limited,
P J Tower, Dalal Street,
Mumbai-400001

Scrip Code: 531681

Security ID: AMERISE

Sub. : Integrated Filing (Financial) for the quarter and Nine-month ended 31st December, 2024

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated 2nd January, 2025, please find attached herewith the Integrated Filing (Financial) for the Quarter and Nine-month ended 31st December, 2024.:

| | | | |
|----------|---|-------------------------------|-------------------------|
| A | Financial Results | Attached as Annexure-1 | |
| B | Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. | Not Applicable | |
| C | Format for disclosing outstanding default on loans and debt securities | Not Applicable | |
| D | Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) | Not Applicable | for this quarter |
| E | Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (Applicable only for annual filing i.e., 4th quarter) | Not Applicable | for this quarter |

Kindly take the same on your record.

Thanking you,

For, **AMERISE BIOSCIENCES LIMITED**


DINESH RATHOD
DIRECTOR

Amerise Biosciences Limited

CIN:- L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

Statement of Unaudited Financial Results for the Quarter Ended December 31, 2024

(Rs. In lacs)

| Sl No. | Particulars | Quarter Ended 31 Dec'2024 | Quarter Ended 30 Sept'2024 | Quarter Ended 31 Dec'2023 | Nine Months Ended 31 Dec'2024 | Nine Months Ended 31 Dec'2023 | Year Ended 31 Mar 2024 |
|-----------|--|------------------------------|-------------------------------|------------------------------|-------------------------------------|-------------------------------------|---------------------------|
| | (Refer Notes Below) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) |
| 1 | Income | | | | | | |
| (a) | Revenue from Operations | - | - | - | - | - | - |
| (b) | Other Income | - | 0.00 | 0.01 | 0.00 | 0.01 | 3.59 |
| | Total Income from Operations (Net) | - | 0.00 | 0.01 | 0.00 | 0.01 | 3.59 |
| 2 | Expenses | | | | | | |
| (a) | Cost of material consumed | - | - | - | - | - | - |
| (b) | Purchase of stock in trade | - | - | - | - | - | - |
| (c) | Changes in inventories of finished goods, work-in-progress, and stock-in-trade | - | - | - | - | - | - |
| (d) | Employee benefit expense | 0.97 | 0.64 | 3.56 | 2.21 | 4.93 | 6.97 |
| (e) | Finance Costs | - | - | - | - | - | - |
| (f) | Depreciation and Amortization Expense | - | - | - | - | - | - |
| (g) | Other expenses | 0.63 | 2.73 | 2.51 | 7.63 | 11.65 | 11.23 |
| | Total Expenses | 1.59 | 3.37 | 6.07 | 9.83 | 16.58 | 18.20 |
| 3 | Profit / (Loss) from operations before exceptional items and Tax (1-2) | (1.59) | (3.37) | (6.06) | (9.83) | (16.57) | (14.61) |
| 4 | Exceptional Items | | | | | | |
| 5 | Profit / (Loss) before Tax (3 ± 4) | (1.59) | (3.37) | (6.06) | (9.83) | (16.57) | (14.61) |
| 6 | Tax Expense | - | - | - | - | - | - |
| 7 | Profit / (Loss) after tax (5 - 6) | (1.59) | (3.37) | (6.06) | (9.83) | (16.57) | (14.61) |
| 8 | Other comprehensive income (Net of Tax) | | | | | | |
| A. | (i) Items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| | (ii) Income tax relating to items that will not be reclassified profit or loss | - | - | - | - | - | - |
| B. | (i) Items that will be reclassified to Profit or Loss | - | - | - | - | - | - |
| 9 | Total comprehensive income (7 ± 8) | (1.59) | (3.37) | (6.06) | (9.83) | (16.57) | (14.61) |
| 10 | Paid-up equity share capital (Face Value of Rs.1/- each) | 660.69 | 660.69 | 660.69 | 660.69 | 660.69 | 660.69 |
| 11 | Other Equity | | | | | | (123.28) |
| 12 | Earnings Per Share (before extraordinary items) (of Rs. 1/- each) (not annualised): | | | | | | |
| | (a) Basic | (0.00) | (0.01) | (0.01) | (0.01) | (0.03) | (0.02) |
| | (b) Diluted | (0.00) | (0.01) | (0.01) | (0.01) | (0.03) | (0.02) |

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 03, 2025. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Ahmedabad
Date : 03rd February, 2025





Limited Review Report

To
The Board of Directors of
AMERISE BIOSCIENCES LIMITED
Ahmedabad


We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **AMERISE BIOSCIENCES LIMITED** ("the Company"), for the Quarter ended on December 31, 2024 and year to date result for the period from 01 April, 2024 to 31 December, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W


CA Amit Shah
Partner
M. No.: 126337
UDIN.: 25126337BMLIBW1749
Place: Vadodara
Date: 03/02/2025

